GlobeNewswire Inc | Jul 20, 2020 06:10PM EDT

July 20, 2020

SAN FRANCISCO, July 20, 2020 (GLOBE NEWSWIRE) -- Hagens Berman urges investors in NanoViricides, Inc. (NNVC) to submit their losses now. The firm is investigating possible securities fraud, and certain investors may have valuable claims. Hagens Berman also encourages persons who may be able to assist the firms investigation to contact its attorneys.

Relevant Period Before July 14, 2020Visit www.hbsslaw.com/investor-fraud/NNVCContact An Attorney Now NNVC@hbsslaw.com 844-916-0895

NanoViricides (NNVC) Investigation:

Hagens Bermans proprietary investigation focuses on whether NanoViricides has misled investors about its activities concerning its development activities related to drugs including a potential treatment for COVID-19.

NanoViricides management has repeatedly touted the companys work on a potential treatment for COVID-19, and other drug development activities during the months leading up to a recent issuance of underwritten securities.

Recently, on July 14, 2020, CNBC reported NanoViricides began a press tour in late January saying it was close to clinical trials for a treatment for COVID-19 and the news appears to have caused its stock price to soar.

CNBC observed the company in the past has made announcements about drug developments during other global health scares such as Ebola, bird flu, and swine flu, and each time the companys stock appeared to rise on the news before falling.

CNBC also quoted a member of the companys scientific advisory board: [t]heyve had something for shingles, theyve had something for hepatitis C, [i]n every case they have supposedly [had] great results in cell studies, [f]or some reason they have some reason not to pursue it, and [a]fter awhile I just didnt like this constant recycling of products and never getting beyond the initial stage.

Were focused on investors losses and whether NanoViricides has accurately represented the work it is doing toward a potential COVID-19 and other treatments, said Reed Kathrein, the Hagens Berman partner leading the investigation. We welcome any and all leads that could assist us in protecting investors.

If you purchased shares of NanoViricides and suffered significant losses, click here to discuss your legal rights with Hagens Berman.

Whistleblowers: Persons with non-public information regarding NanoViricides should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email NNVC@hbsslaw.com.

About Hagens Berman Hagens Berman is a national law firm with nine offices in eight cities around the country and eighty attorneys. The firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the firm and its successes is located at hbsslaw.com. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.

Contact: Reed Kathrein, 844-916-0895